Quintiles/AstraZeneca Announce Strategic Alliance
Quintiles announced that it has entered into a clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.
According to a release, Quintiles will assume the operational responsibilities for the majority of AstraZeneca’s clinical pharmacology delivery. The alliance is extensive and involves the engagement of a sole provider for clinical pharmacology delivery, and a simple, standardized pricing model. Also, as well as clinical conduct and medical oversight of studies, the agreement covers a range of activities across the end-to-end study process.
Quintiles’ network of clinical pharmacology facilities are located across Europe and the United States, with plans to open a unit in Asia in 2010. These facilities are connected via integrated data platforms using advanced electronic data capture and reporting.
An article that appeared in our June issue, based on a survey of CROs and Pharma managers, discussed this topic of changing relationship structures.
Another example of strategic alliances is between Covance and Lilly from last summer, where Covance took on Lilly’s non-GLP toxicology, in vivo pharmacology, quality control laboratory, and imaging services, and Lilly signed to provide Covance $1.6B in services over 10 years.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
